Summit Therapeutics PLC (SMMT) — Cash Flow Reinvestment Rate
Summit Therapeutics PLC (SMMT) has a Cash Flow Reinvestment Rate of 152.67x as of December 2022, reinvesting $646.06 Million (capex $994.38K plus investments $-645.06 Million) from operating cash flow of $4.23 Million. See Summit Therapeutics PLC (SMMT) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Summit Therapeutics PLC Cash Flow Reinvestment Rate (2004–2016)
Historical reinvestment intensity for Summit Therapeutics PLC across 2 annual periods. For the full cash flow conversion analysis, see cash efficiency ratio of Summit Therapeutics PLC.
Annual Cash Flow Reinvestment Rate for Summit Therapeutics PLC (2004–2016)
Year-by-year capital reinvestment analysis for Summit Therapeutics PLC. See SMMT financial flexibility score to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2016 | 0.01x | $209.99K | $15.18 Million | $110.00K | ▼ -96.9% |
| 2004 | 0.44x | $13.18K | $29.74K | $13.18K | — |